BioNTech (BNTX) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• BioNTech will report Q1 2026 results before the market opens on May 5, with analysts forecasting EPS of ($2.5429) and revenue of $220.02 million and a conference call scheduled for 8:00 AM ET.
• Shares opened at $102.06 and were trading down ~3.2% with a market cap of $25.81 billion, while analysts' consensus rating is Moderate Buy and the average price target is $133.13.
• COO Sierk Poetting sold 50,000 shares at an average price of $110.56 under a Rule 10b5-1 plan for $5.528 million, cutting his holding by 11.13%; insiders own 19.20% of the stock.

BioNTech (NASDAQ:BNTX - Get Free Report) is expected to issue its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of ($2.5429) per share and revenue of $220.0220 million for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:00 AM ET.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. The business had revenue of $1.06 billion during the quarter. BioNTech had a negative return on equity of 4.76% and a negative net margin of 38.09%. On average, analysts expect BioNTech to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

BioNTech Trading Down 3.2%

Shares of BNTX stock opened at $102.06 on Tuesday. The company has a market cap of $25.81 billion, a P/E ratio of -19.48 and a beta of 1.58. BioNTech has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The stock has a 50 day simple moving average of $97.89 and a two-hundred day simple moving average of $101.12. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.49 and a current ratio of 7.54.

Analyst Ratings Changes

Several equities research analysts have recently commented on BNTX shares. Truist Financial upgraded BioNTech to a "strong-buy" rating in a report on Wednesday, March 25th. Bank of America restated a "buy" rating and set a $128.00 price objective on shares of BioNTech in a report on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of BioNTech in a report on Tuesday, March 17th. The Goldman Sachs Group restated a "buy" rating on shares of BioNTech in a report on Wednesday, March 11th. Finally, Berenberg Bank restated a "buy" rating on shares of BioNTech in a report on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $133.13.

Insider Activity

In related news, COO Sierk Poetting sold 50,000 shares of BioNTech stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the transaction, the chief operating officer owned 399,387 shares of the company's stock, valued at $44,156,226.72. The trade was a 11.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BNTX. EFG International AG purchased a new position in shares of BioNTech during the fourth quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd boosted its position in shares of BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company's stock valued at $30,000 after buying an additional 260 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock valued at $60,000 after buying an additional 305 shares during the last quarter. NewEdge Advisors LLC purchased a new position in shares of BioNTech during the first quarter valued at approximately $167,000. Finally, Osaic Holdings Inc. boosted its position in shares of BioNTech by 27.3% during the second quarter. Osaic Holdings Inc. now owns 1,949 shares of the company's stock valued at $208,000 after buying an additional 418 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.